Companies

Bristol Myers Squibb

9 articles

Industry NewsBristol Myers SquibbBioPharma Dive

Bristol Myers folds research into development as its research chief leaves

  • Bristol Myers is merging its research and development departments; Cristian Massacesi, now chief medical officer and head of development, becomes head of R&D on Jan. 1, 2027.
  • Research chief Robert Plenge will leave, staying through March 2027 for the transition. The company says the change speeds decisions and portfolio management.
  • The reshuffle comes ahead of the Eliquis patent cliff, after trial setbacks for Cobenfy and Camzyos and earlier cost cuts.
PointsBased on public reports

Putting a development executive in charge of both halves signals a shift toward late-stage execution over exploratory research, which fits a company that has to refill revenue before Eliquis erodes. The risk is the usual one: a unified R&D organization optimizes for near-term clinical probability and can starve early discovery. Watch whether external deals take over the role research used to play in feeding the pipeline.

Industry NewsBeeline Medicines / Bristol Myers SquibbFierce Biotech

Beeline's Oral Lupus Drug, Spun Out of Bristol Myers, Beats Placebo at All Three Doses

  • Beeline's Phase 2 trial of afimetoran, an oral TLR7/8 inhibitor licensed from Bristol Myers Squibb, met its primary endpoint in systemic lupus erythematosus.
  • All three doses beat placebo on the SRI-4 response rate at week 48 in a dose-ranging study of adults on background therapy.
  • No new safety signals were reported; Beeline plans pivotal trials in SLE and cutaneous lupus, with full data at a coming congress.
PointsBased on public reports

A clean win at every dose is what Beeline needed to justify taking a drug BMS chose to shelve, and it validates the spin-out model for pipeline assets big pharma deprioritizes. The topline gave no effect sizes, though, and an SRI-4 gap over placebo has to be weighed against the other oral lupus entrants. Watch the dose-response shape and infection rates before pricing in a pivotal-trial success.

Industry NewsAbbVie / Bristol Myers SquibbBioSpace

Two Neuro Mega-Deals, Two Approvals, Still No Clear Winner

  • AbbVie paid $8.7 billion for Cerevel and Bristol Myers Squibb $14 billion for Karuna in late 2023. Each now has an approved drug: Cobenfy since 2024 and AbbVie's Parkinson's drug Juvmo since September.
  • Emraclidine failed two Phase 2 schizophrenia studies, while Cobenfy sales have repeatedly missed expectations; its Alzheimer's psychosis readouts have slipped to early 2027.
  • Analysts see it as too early to call, with Juvmo's peak sales unlikely to fully justify the Cerevel price.
PointsBased on public reports

The two deals were bets on different risks: BMS bought a de-risked first-in-class launch and is now paying for slow uptake and tolerability, while AbbVie bought earlier-stage assets and absorbed a clinical failure. Cobenfy's Alzheimer's psychosis data in 2027 is the swing factor, since it could expand the label well beyond a crowded schizophrenia market.

Industry NewsBristol Myers SquibbBioSpace

Bristol Myers ends PRX019 neurodegeneration program after Phase 1 as quarterly revenue climbs

  • Bristol Myers Squibb will not advance PRX019, a neurodegeneration antibody licensed from Prothena in 2024, after reviewing Phase 1 data; the tau-targeting moponetug collaboration continues.
  • It also discontinued ORM-6151, an early degrader-antibody conjugate for blood cancer acquired from Orum in 2023.
  • Third-quarter revenue rose 7% to $13.1 billion, and full-year revenue guidance was raised to $49.75-50.25 billion.
PointsBased on public reports

Two cuts in one print, against a 7% revenue beat, say BMS is pruning aggressively to fund its growth portfolio. Walking away from PRX019 after Phase 1 while keeping the tau antibody leaves Prothena's BMS exposure concentrated in a single bet, and it signals that BMS wants neuro assets with clearer differentiation, not option-style optionality.

Industry NewsBristol Myers SquibbBioSpace

BMS discloses septic pneumonia death of multiple sclerosis patient in CAR-T trial

  • A multiple sclerosis patient in a Bristol Myers Squibb autoimmune CAR-T study died of septic pneumonia, the company disclosed.
  • The disclosure came before a Phase 1 Breakfree-2 data presentation at the ACTRIMS-ECTRIMS meeting.
  • It follows BMS's late-summer pause of certain trials of zolacabtagene autoleucel.
PointsBased on public reports

Two safety events in roughly two months is a pattern investors and regulators will not ignore: a pause in late summer, now a patient death in MS. Moving CAR-T from oncology into autoimmune disease means asking patients with manageable conditions to accept lymphodepletion risk, so the tolerability bar is far higher. Details are thin, but BMS's disclosure ahead of the Breakfree-2 data looks like deliberate risk management.

Industry NewsPathos AI / Bristol Myers SquibbEndpoints News

Pathos AI closes a $237M Series E and signs a neuroscience deal with Bristol Myers

  • AI-driven biotech Pathos AI raised a $237 million Series E at a $3 billion valuation.
  • Endpoints notes the round came in below the $300 million the company had been associated with.
  • The company also signed a neuroscience partnership with Bristol Myers Squibb; terms were not in the feed text.
PointsBased on public reports

A $3B valuation on a sub-target raise suggests investors still pay up for AI-biotech, but not at any size. The BMS neuro tie-up matters more as validation: big pharma seems to prefer partnering on difficult CNS biology to buying platforms outright. I'd watch whether the deal carries real milestones or just platform fees.

Industry NewsMaruho / Bristol Myers SquibbAnswersNews

Maruho and BMS Partner on Japan Sales for TYK2 Inhibitor Sotyktu

  • Maruho and Bristol Myers Squibb (BMS) signed a Japan sales partnership for Sotyktu (deucravacitinib), BMS's oral TYK2 inhibitor, starting October 1, 2026.
  • Maruho will handle domestic sales and distribution, promoting the drug in dermatology and rheumatology, while BMS continues promotion in rheumatology.
  • Sotyktu is approved for plaque, pustular and erythrodermic psoriasis, with a psoriatic arthritis indication added in May 2026.
PointsBased on public reports

BMS ceding Japan commercial lead to Maruho is a tacit admission that dermatologist relationships beat global scale here — the classic foreign-innovator/domestic-specialist access play. Adding rheumatology promotion right after the May PsA nod signals urgency to outrun oral JAK rivals before positioning hardens. For Maruho, it's low-risk topline padding that fits its derm book without R&D exposure.

Industry NewsBristol Myers Squibb / Orum TherapeuticsEndpoints News

Bristol Myers Squibb Discontinues Orum-Partnered AML Drug ORM-6151 After Phase 1 Review

  • Bristol Myers Squibb (BMS) has discontinued ORM-6151, an investigational degrader-antibody conjugate (DAC) licensed from Orum Therapeutics, after reviewing Phase 1 clinical data.
  • ORM-6151 pairs an anti-CD33 antibody with a GSPT1 molecular-glue degrader payload, built on Orum's TPD² (targeted protein degradation + targeted delivery) platform; DACs are a newer conjugate class that deliver a protein-degrading payload rather than the cytotoxins used in classic antibody-drug conjugates (ADCs).
  • The drug was in a Phase 1 trial for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
  • BMS licensed ORM-6151 from Orum in 2023 for a $100 million upfront payment.
  • BMS notified Orum of the discontinuation on September 16, 2026, ending its obligation for up to $80 million in further milestone payments; Orum keeps the $100 million upfront already received.
PointsBased on public reports

The read here isn't that DACs are dead — GSPT1 degrader payloads carry known hematologic toxicity liabilities independent of the antibody delivery mechanism, so this looks more like a target/payload combination failing than an indictment of Orum's TPD² platform. Still, ORM-6151 was the most advanced, highest-profile DAC sitting inside Big Pharma hands, so its exit tightens scrutiny on the whole conjugate-degrader class before any asset reaches pivotal trials. The deal math is the sharper lesson: Orum banked its full $100M upfront and forfeits nothing, while BMS ate the Phase 1 spend and walks from up to $80M in milestones — a familiar structure where biotechs get paid for optionality, not outcomes. For Orum, losing its marquee partnered program right as it needs to prove platform durability to future licensees is the real overhang.

Industry NewsNovartis / Bristol Myers SquibbFierce Biotech

Novartis and BMS Pause Autoimmune CAR-T Trials After Safety Events

  • Novartis and Bristol Myers Squibb separately paused clinical trials of experimental autologous CAR-T cell therapies being developed for autoimmune and neurological conditions, including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis and myasthenia gravis.
  • Novartis halted eight studies of its candidate, rap-cel (rapcabtagene autoleucel), around August 24 after three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS), a severe systemic inflammatory reaction.
  • Bristol Myers Squibb paused enrollment in trials of its own CD19-targeted CAR-T, zola-cel, describing "transient and reversible inflammatory events" markedly less severe than the deaths Novartis reported, and saying the therapy's safety profile otherwise remains consistent with other CAR-T treatments.
  • Both companies said they are reviewing clinical data with independent safety boards and regulators before deciding on next steps for their affected programs.
PointsBased on public reports

Autoimmune CAR-T was the industry's hottest oncology-to-new-indication pivot — Kyverna, Cabaletta, Autolus and multiple academic programs are all racing the same CD19 mechanism, so this becomes a class-level scrutiny event, not just a Novartis/BMS problem. The two signals aren't equivalent: three IEC-HS deaths is a materially different regulatory conversation than BMS's "reversible" events — expect FDA to treat rap-cel far more cautiously than zola-cel, even though headlines pair them. Multi-trial pauses cost both companies precious time on programs meant to diversify beyond their legacy oncology CAR-T franchises (Kymriah, Breyanzi) into a much larger chronic-disease market. If regulators respond with class-wide holds or REMS-style safeguards, smaller autoimmune CAR-T players inherit the delay and diligence burden without the balance sheets to absorb it.